[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345399-105":59,"doc-detail-345399-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","efficacy-of-olaparib-in-advanced-cancers-with-somatic-or-germline-mutations-in-bap1-bard1-brip1-and-palb2","Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2","","Olaparib is an approved PARP inhibitor for several cancer types with BRCA1/2 mutations and/or homologous recombination deficiency (HRD) genes. This investigator-initiated open-label basket phase II trial assesses olaparib efficacy in advanced tumors carrying likely pathogenic germline or somatic mutations in HR genes after progression on standard-of-care. Cohorts were stratified by mutation origin and gene, reporting a case series for rarer alterations. Objective responses were observed in BAP1, BARD1, BRIP1, and PALB2 cohorts, with no responses in specified other HR-related cohorts.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-of-olaparib-in-advanced-cancers-with-somatic-or-germline-mutations-in-bap1-bard1-brip1-and-palb2/345399/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-of-olaparib-in-advanced-cancers-with-somatic-or-germline-mutations-in-bap1-bard1-brip1-and-palb2/345399.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on olaparib?","Question",{"text":112,"@type":113},"To evaluate the efficacy of olaparib in advanced cancers that harbor likely pathogenic germline or somatic mutations in homologous recombination (HR) genes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped for treatment evaluation?",{"text":117,"@type":113},"Patients were enrolled in a basket phase II trial, with cohorts stratified by whether they had somatic or germline mutations in the same HR-related gene.",{"name":119,"@type":110,"acceptedAnswer":120},"Which gene cohorts showed objective responses to olaparib?",{"text":121,"@type":113},"Objective responses were detected in the BAP1, BARD1, BRIP1, and PALB2 cohorts.",{"name":123,"@type":110,"acceptedAnswer":124},"What was the key conclusion about clinical activity?",{"text":125,"@type":113},"Olaparib demonstrated meaningful clinical activity across different cancer types with somatic or germline mutations in BAP1, BARD1, BRIP1, and PALB2.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345399,1790135401,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ORIGINAL ARTICLE  \nEfficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2  \nS. Joris1 ∗, H. Denys2, J. Collignon3, M. Rasschaert4, D. T. de Roodenbeke5, F. P. Duhoux6, J. L. Canon7, S. Tejpar8, J. Mebis9,  \nL. Decoster1, P. Aftimos5 & J. De Grève1 , 10  \n1Department of Medical Oncology, UZ Brussel, Brussel; 2Department of Medical Oncology, University Hospital Ghent, Ghent; 3Department of Medical Oncology, CHU Sart Tilman, Liège; 4Department of Medical Oncology, UZA, Antwerpen; 5Department of Medical Oncology, Institut Jules Bordet-Université libre de Bruxelles, Brussel; 6Department of Medical Oncology, Cliniques universitaires Saint-Luc, Brussel; 7Department of Medical Oncology, GHdC, Charlerloi; 8Department of Medical Oncology, UZ Leuven, Leuven; 9Department of Medical Oncology, Jessa Ziekenhuizen, Hasselt; 10Department of Medical Genetics, UZ Brussel, Brussels, Belgium  \nAvailable online xxx  \nBackground: Olaparib is registered for use in ovarian, breast, pancreatic and prostate cancers with a BRCA1/2 mutation and/or mutations in other homologous recombination deficiency (HRD) genes. HRD gene mutations are also found in other cancer types, and these cancers may also benefit from olaparib therapy. We aimed to evaluate the efficacy of olaparib in advanced cancers harboring a (likely) pathogenic germline or somatic mutation in a gene involved in homologous recombination (HR) .  \nPatients and methods: This investigator-initiated, open-label, basket phase II trial evaluates the efficacy of olaparib inpatients with advanced tumors harboring HR gene mutations following progression on standard-of-care therapies. Cohorts were stratified based on the presence of either somatic or germline mutations in the same HR-related gene. Although results from the completed cohorts have been previously published, this report presents a case series focusing on cohorts with rare gene alterations.  \nResults: In patients who harbor a tumor mutation in ARID1A, ATR, ATRX, BLM, CDK12, CHEK1, DDR2, ERCC4, FANCE, GEN1, MRE11A, NBN, POLE, RAD21, RAD50, RAD51C, RAD51D, RAD52 and SLX4, no responses were observed. In the BAP1, BARD1, BRIP1 and PALB2 cohorts, objective responses were detected.  \nConclusion: Olaparib demonstrated meaningful clinical activity across different cancer types with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2 .  \nKey words: olaparib, BAP1, BARD1, BRIP1, PALB2  \nINTRODUCTION  \nFor many decades, treatment decisions have been guided by patient characteristics, tumor histology and hormone receptor status to guide our treatment decisions. The introduction of next-generation sequencing (NGS) for solid tumors has significantly expanded the spectrum of predictive markers, thereby advancing the development of stratified medicines over the last three decades. Identifying genomic alterations, such as mutations and gene fusions, informs the development and subsequent use of targeted therapies.1 Genome-driven therapies are typically developed for tumor-specific indications. However, many drugsensitizing mutations are also present in cancer types  \n*Correspondence to: Prof. Sofie Joris, MD, PhD, Department of Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium. Tel:+32-477-64-15  \n[E-mail:](E-mail: Sofie.Joris@uzbrussel.be)[ Sofie.Joris@uzbrussel.be](E-mail: Sofie.Joris@uzbrussel.be) (S. Joris).  \n2059-7029/© 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nbeyond those for which treatments are approved. Targeting these drivers in off-label cancer types can yield significant benefit, although the magnitude of response may not always match that observed in the lead indications.  \nGenomic instability resulting from defects in the DNA damage ","cbCaibEtK6b6oL5W","https://ap.wps.com/l/cbCaibEtK6b6oL5W","pdf",574784,"English","# Background\n# Patients and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the main goal of this study on olaparib?\",\"answer\":\"To evaluate the efficacy of olaparib in advanced cancers that harbor likely pathogenic germline or somatic mutations in homologous recombination (HR) genes.\"},{\"question\":\"How were patients grouped for treatment evaluation?\",\"answer\":\"Patients were enrolled in a basket phase II trial, with cohorts stratified by whether they had somatic or germline mutations in the same HR-related gene.\"},{\"question\":\"Which gene cohorts showed objective responses to olaparib?\",\"answer\":\"Objective responses were detected in the BAP1, BARD1, BRIP1, and PALB2 cohorts.\"},{\"question\":\"What was the key conclusion about clinical activity?\",\"answer\":\"Olaparib demonstrated meaningful clinical activity across different cancer types with somatic or germline mutations in BAP1, BARD1, BRIP1, and PALB2.\"}]","Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2 | PDF",1790057541,18,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4a104a667bace77f5820e53808af3f8.webp",983,1269,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6099f63fabf92898457d2da4a98c0a0.webp",982,1268,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f8b11413755459485e81082976c25e1.webp",981,1266,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/972ec3300ea984e10ac91905618bf5ec.webp",980,1265]